Filings Flow: Amyris, Inc: Temasek Holdings (Private) Ltd Opened Big New Position

Filings Flow: Amyris, Inc: Temasek Holdings (Private) Ltd Opened Big New Position

The New Temasek Holdings (Private) Ltd Holding in Amyris, Inc

Temasek Holdings (Private) Ltd filed with the SEC SC 13D/A form for Amyris, Inc. The form can be accessed here: 000119312516759646. As reported in Temasek Holdings (Private) Ltd’s form, the filler as of late owns 29.2% or 70,035,209 shares of the Materials–company.

Amyris, Inc stake is a new one for the for this institutional investor and it was filed because of activity on November 3, 2016. We feel this shows Temasek Holdings (Private) Ltd’s positive view for the stock.

Amyris, Inc Institutional Sentiment

Latest Security and Exchange filings show 45 investors own Amyris, Inc. The institutional ownership in Q3 2015 is low, at 26.59% of the outstanding shares. This is increased by 38337531 the total institutional shares. 62489443 were the shares owned by these institutional investors. In total 5 funds opened new Amyris, Inc stakes, 12 increased stakes. There were 15 that closed positions and 12 reduced them.

Concourse Capital Management Llc is an institutional investor bullish on Amyris, Inc, owning 43110 shares as of Q3 2015 for 0.04% of its portfolio. Tpg Group Holdings Sbs Advisors Inc owns 3978660 shares or 0.04% of its portfolio. CA Connective Capital Management Llc have 3.96% of their stock portfolio for 961537 shares. Further, Temasek Holdings Private Ltd reported stake worth 0.81% of its US stock portfolio. The CA First Republic Investment Management Inc owns 30000 shares. Amyris, Inc is less than 0.01% of the manager’s US portfolio.

Business Profile

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment decreased to 0.39 in 2016 Q2. Its down 1.25, from 1.64 in 2016Q1. The ratio fall, as 19 funds sold all Amyris Inc shares owned while 9 reduced positions. 2 funds bought stakes while 9 increased positions. They now own 82.40 million shares or 3.93% less from 85.77 million shares in 2016Q1.

Lazard Asset Management Limited Liability has 0% invested in the company for 240,535 shares. California Public Employees Retirement Systems accumulated 80,300 shares or 0% of the stock. Millennium Limited Company has 115,028 shares for 0% of their US portfolio. Moreover, Northern Trust Corp has 0% invested in Amyris Inc (NASDAQ:AMRS) for 106,262 shares. Geode Mgmt Ltd Liability Company owns 347,867 shares or 0% of their US portfolio. The Ontario – Canada-based Royal Retail Bank Of Canada has invested 0% in Amyris Inc (NASDAQ:AMRS). State Street Corp holds 0% or 24,081 shares in its portfolio. Manufacturers Life Ins The holds 0% of its portfolio in Amyris Inc (NASDAQ:AMRS) for 4,825 shares. Jacobs Levy Equity has invested 0% of its portfolio in Amyris Inc (NASDAQ:AMRS). Natl Bank Of America Corp De last reported 0% of its portfolio in the stock. Goldman Sachs accumulated 22,474 shares or 0% of the stock. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Invest Mgmt Corporation accumulated 0% or 33,471 shares. First Advsr L P has invested 0% of its portfolio in Amyris Inc (NASDAQ:AMRS). Deutsche National Bank Ag last reported 0% of its portfolio in the stock. Concourse Capital Mgmt Limited Liability, a Georgia-based fund reported 43,110 shares.

About 21,084 shares traded hands. Amyris Inc (NASDAQ:AMRS) has declined 23.76% since April 4, 2016 and is downtrending. It has underperformed by 24.85% the S&P500.

Amyris, Inc. is an integrated industrial biotechnology company. The company has a market cap of $171.32 million. The Firm is engaged in research and development and sales of fuels and farnesene-derived products. It currently has negative earnings. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances , solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Amyris Inc (NASDAQ:AMRS) Ratings Coverage

Out of 3 analysts covering Amyris Inc (NASDAQ:AMRS), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. $4 is the highest target while $2 is the lowest. The $3.33 average target is 344.00% above today’s ($0.75) stock price. Amyris Inc has been the topic of 3 analyst reports since November 10, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Rodman & Renshaw on Tuesday, November 10. As per Tuesday, November 10, the company rating was initiated by H.C. Wainwright. Cowen & Co maintained Amyris Inc (NASDAQ:AMRS) on Thursday, March 10 with “Market Perform” rating.

More news for Amyris Inc (NASDAQ:AMRS) were recently published by: Fool.com, which released: “Why Amyris, Inc. Stock Plunged 24%” on November 03, 2016. Streetinsider.com‘s article titled: “Form 4 AMYRIS, INC. For: Nov 01 Filed by: Cherry Joel” and published on November 03, 2016 is yet another important article.

According to Zacks Investment Research, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA.”

AMRS Company Profile

Amyris, Inc., incorporated on April 15, 2010, is an integrated industrial biotechnology company. The Firm is engaged in research and development and sales of fuels and farnesene-derived products. The Firm is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Firm intends to apply its technology to the development of pharmaceutical products. The Firm focuses on a renewable hydrocarbon molecule called farnesene (Biofene), which forms the basis for a range of products, including emollients, flavors and fragrance oils and diesel fuel. The Company’s subsidiaries are Amyris Brasil Ltda. and Amyris Fuels, LLC.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags:

Related posts

Leave a Comment